

## DRUG DISCOVERY TODAY

## Editorial

**Editor:** Steve Carney  
**Content Development Manager:** Pien van Spijker  
**Journal Manager:** Bharathi Sims  
**Publisher:** Fernanda Ogochi  
**Editorial Enquiries:**  
*Drug Discovery Today*  
 Elsevier  
 125 London Wall, London, EC2Y 5AS, UK  
 Tel: +44 (0) 20 8439 5525  
 Fax: +44 (0)1865 853067  
 Email: ddt@drugdiscoverytoday.com

## ADVISORY EDITORIAL BOARD

**Jürgen Bajorath** *University of Bonn, Germany*  
**Walter Blackstock** *Experimental Therapeutics Centre, Singapore*  
**David Brayden** *University College Dublin, Ireland*  
**Paul Caron** *Integrated Profiling, USA*  
**David Cavalla** *Numedica Ltd., UK*  
**David Clark** *Argenta Discovery, UK*  
**Dalia Cohen** *ALN Associates, USA*  
**Donald Daley** *Argenta Discovery, UK*  
**Sean Ekins** *Collaborations in Chemistry, USA*  
**Hans-Peter Fischer** *GeneData, Switzerland*  
**Peter Ghazal** *University of Edinburgh, UK*  
**Christopher M. Hill** *Merck, USA*  
**Nick Hird** *Takeda Chemical Industries, Japan*  
**Enoch Huang** *Pfizer, USA*  
**Thomas Joos** *University of Tuebingen, Germany*  
**Vincent H.L. Lee** *Chinese University of Hong Kong, China*  
**David Lewin** *Yale University, USA*  
**Christopher A. Lipinski** *Meliior Discovery, USA*  
**Lorenz Mayr** *AstraZeneca, UK*  
**Nick Meanwell** *Bristol-Myers Squibb, USA*  
**BK Muralidhara** *Acceleron Pharma Inc, USA*  
**Mark Murcko** *Disruptive Biomedical, LLC, USA*  
**Fajun Nan** *Shanghai Institute of Materia Medica, China*  
**Pradeep Nathan** *Experimental Medicine, GSK and University of Cambridge*  
**Gitte Neubauer** *Cellzome, Germany*  
**Eric Neumann** *Clinical Semantics Group Consulting, USA*  
**Tim Peakman** *UK Biobank, UK*  
**Norton Peet** *Microbiotix, Inc., USA*  
**Manuel Peitsch** *Swiss Institute of Bioinformatics, Switzerland*  
**Kurt Rasmussen** *Eli Lilly and Co. Ltd., USA*  
**Janice Reichert** *Reichert Biotechnology Consulting LLC, MA, USA*  
**John Reidhaar-Olson** *Albert Einstein College of Medicine, New York, USA*  
**Mike Romanos** *Crescendo Biologics, Cambridge, UK*  
**Raymond C. Rowe** *Intelligensys, UK*  
**Andreas Russ** *University of Oxford, UK*  
**Esther Schmid** *EFS Strategy and Business Consulting, UK*  
**Jonathan Sheldon** *Translational Medicine, Oracle, UK*  
**Michael Snyder** *Stanford University, USA*  
**Susie Stephens** *Johnson & Johnson, USA*  
**Robert Strausberg** *Ludwig Institute for Cancer Research, New York, USA*  
**Yuichi Sugiyama** *University of Tokyo, Japan*  
**David Szymkowski** *Xencor, USA*  
**Nick Terrett** *Ensemble Discovery, USA*  
**Vladimir Torchilin** *Northeastern University, Boston, USA*  
**Mark Whittaker** *Evotec OAI, UK*  
**Hans Winkler** *Janssen Pharmaceutica, Belgium*  
**Limsoon Wong** *National University of Singapore*  
**X.F. Steven Zheng** *Robert Wood Johnson Medical School, USA*

DRUG DISCOVERY  
TODAY

## REVIEWS (continued)

## POST SCREEN

- 1166 Neuropharmacokinetics: a bridging tool between CNS drug development and therapeutic outcome**  
*Swati Chaturvedi, Mamunur Rashid, Mohd Yaseen Malik, Arun Agarwal, Sandeep K. Singh, Jiaur R. Gayen and Muhammad Wahajuddin*
- 1176 Exploration of biomedical dendrimer space based on in-vitro physicochemical parameters: key factor analysis (Part 1)**  
*Serge Mignani, João Rodrigues, René Roy, Xiangyang Shi, Valentin Ceña, Saïd El Kazzouli and Jean-Pierre Majoral*
- 1184 Exploration of biomedical dendrimer space based on in-vivo physicochemical parameters: Key factor analysis (Part 2)**  
*Serge Mignani, João Rodrigues, René Roy, Xiangyang Shi, Valentin Ceña, Saïd El Kazzouli and Jean-Pierre Majoral*
- 1193 Therapy for glioblastoma: is it working?**  
*Edward D. Zanders, Fredrik Svensson and David S. Bailey*
- 1202 The role of mitochondrial DNA in breast tumors**  
*Marjolein J.A. Weerts, Stefan Sleijffer and John W.M. Martens*
- 1209 Walking a tightrope: drug discovery in visceral leishmaniasis**  
*Rafael Balaña-Fouce, M. Yolanda Pérez Pertejo, Bárbara Domínguez-Asenjo, Camino Gutiérrez-Corbo and Rosa M. Reguera*
- 1217 Organ-on-a-chip technology: turning its potential for clinical benefit into reality**  
*Malcolm Haddrick and Peter B. Simpson*
- 1224 Expanding the activity spectrum of antiviral agents**  
*Aleksandr Ianevski, Petter I. Andersen, Andres Merits, Magnar Bjørås and Denis Kainov*

## FORTHCOMING ARTICLES:

- Müller cells as a target for retinal therapy.**  
*By Joke Devoldere, Karen Peynshaert, Stefaan C. De Smedt, Katrien Remaut.*
- Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties.**  
*By Astrid Subrizi, Eva M. del Amo, Viktor Korzhakov-Vlakh, Tatiana Tennikova, Marika Ruponen and Arto Urtti.*
- Modified cells as potential ocular drug delivery systems.**  
*By Tatiana Tennikova<sup>1</sup> and Arto Urtti*
- Connexin43 hemichannels: a potential drug target for the treatment of diabetic retinopathy.**  
*By Odunayo O. Mugisho, Colin R. Green, Jie Zhang, Monica L. Acosta and Ilva D. Rupenthal.*